Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
GAITHERSBURG, Md., Jan. 03, 2018 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2018:
- J.P. Morgan & Co. – 36th Annual Healthcare Conference
San Francisco, CA
January 8-11, 2018
- RBC Capital Markets – 2018 Global Healthcare Conference
New York, NY
February 21-22, 2018
- Cowen & Co. – 38th Annual Health Care Conference
Boston, MA
March 12-14, 2018
Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as the information becomes available.
For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]
Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]
